IDM's Mepact recommended for osteosarcoma in the EU
This article was originally published in Scrip
Executive Summary
IDM Pharma's immunotherapy Mepact (mifamurtide, or L-MTP-PE) has after some delay received a positive opinion from the EU's CHMPrecommending marketing authorisation for the treatment of patients with non-metastatic, resectable osteosarcoma, an orphan indication.